Almac Diagnostics announced today that it has joined the Personalized Medicine Coalition (PMC).
The coalition is an independent non-profit group comprised of leading academic, industrial, patient and provider organizations, who are dedicated to the advancement, understanding and adoption of personalized medicine. The group provides leadership surrounding the issue and serves as a forum for discussion, education and advocacy.
Professor Paul Harkin, president and managing director of Almac Diagnostics, said: “At Almac we are committed to the advancement of patient care through translational genomic solutions. We believe we can positively contribute to the progression of personalized medicine through our expertise in biomarker discovery and validation, bioinformatics solutions and genomic services, including our proprietary cancer DSA™ technology. We are looking forward to working alongside other like-minded organizations and playing a role in the acceleration of personalized medicine, and ultimately its benefits to patient care.”
Edward Abrahams, executive director of PMC added: “The PMC is especially pleased that Almac Diagnostics has joined its efforts to create a friendlier landscape for the advancement of personalized medicine. The PMC seeks to expand its international focus, and Almac Diagnostics is well positioned to contribute to that goal.”
Since its launch in 2004, the coalition has grown to over 140 members, providing a forum for the public, policymakers, government officials and private sector healthcare leaders, to further the public interest in personalized medicine and identify policies that will accelerate its adoption. The PMC has engaged with a wide range of organisations, including the FDA, National Human Genome Research Institute, the Centre for Medicare and Medicaid Services, among others.
